CAL
DAWN

Capital Analysts LLC’s Day One Biopharmaceuticals DAWN Stock Holding History

Capital Analysts LLC’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750
Closed -$16K – 986
2022
Q4 		$16K Hold
750
– – ﹤0.01% 794
2022
Q3 		$15K Hold
750
– – ﹤0.01% 746
2022
Q2 		$13K Hold
750
– – ﹤0.01% 759
2022
Q1 		$7K Hold
750
– – ﹤0.01% 784
2021
Q4 		$13K Hold
750
– – ﹤0.01% 773
2021
Q3 		$18K Hold
750
– – ﹤0.01% 712
2021
Q2 		$17K Buy
+750
New +$15.6K ﹤0.01% 685

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Analysts LLC's DAWN Position: Q1 2023 in Review

Capital Analysts LLC sold out of Day One Biopharmaceuticals (DAWN) in Q1 2023, closing a stake of 750 shares — an estimated $16K sold.

Capital Analysts LLC first reported a position in DAWN in Q2 2021 and held it in 7 quarters. The position peaked at $18K in Q3 2021. 126 funds tracked by Wall St. Rank hold DAWN as of Q1 2023.

  • Capital Analysts LLC reported no remaining Day One Biopharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Capital Analysts LLC sold 750 Day One Biopharmaceuticals shares in Q1 2023, an estimated $16K.
  • Capital Analysts LLC first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Capital Analysts LLC's Day One Biopharmaceuticals position peaked at $18K in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2023.

Based on Capital Analysts LLC's 13F filing for Q1 2023, filed 5 May 2023.